Skip to main content
SpringerLink
Log in
Book cover

Arzneiverordnungs-Report 2016 pp 209–235Cite as

Hemmstoffe des Renin-Angiotensin-Systems

  • Chapter

  • 2111 Accesses

Zusammenfassung

Hemmstoffe des Renin-Angiotensin-Systems (RAS) gehören zu den erfolgreichsten Arzneimitteln zur Behandlung von Hypertonie, Herz- und Nierenkrankheiten. Angiotensinrezeptorantagonisten gewinnen nach Auslaufen des Patentschutzes mehrerer Sartane weitere Marktanteile. Dagegen verliert erneut deutlich der bisher einzige Renininhibitor Aliskiren und sinkt auf 0,28% der Gesamtgruppe.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   64.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Ahmed AK, Kamath NS, El Kossi M, El Nahas AM (2010): The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease. Nephrol Dial Transplant 25: 3977–3982

    Google Scholar 

  • Antoniou T, Camacho X, Yao Z, Gomes T, Juurlink DN, Mamdani MM (2013): Comparative effectiveness of angiotensin-receptor blockers for preventing macrovascular disease in patients with diabetes: a population-based cohort study. Cmaj 185: 1035–1041

    Google Scholar 

  • Arzneimittelkommission der Deutschen Ärzteschaft (2004): Empfehlungen zur Therapie der arteriellen Hypertonie. 2. Auflage, Arzneiverordnung in der Praxis, Band 31, Sonderheft 2 (Therapieempfehlungen), Internet: www.akdae.de/35/74_Hypertonie_2004_2Auflage.pdf

  • Bakris GL, Sarafidis PA, Weir MR, Dahlöf B, Pitt B, Jamerson K, Velazquez EJ, Staikos-Byrne L, Kelly RY, Shi V, Chiang YT, Weber MA; ACCOMPLISH Trial investigators (2010): Renal outcomes with diff erent fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 375: 1173–1181

    Google Scholar 

  • Bangalore S, Kumar S, Kjeldsen SE, Makani H, Grossman E, Wetterslev J, Gupta AK, Sever PS, Gluud C, Messerli FH (2011a): Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324 168 participants from randomised trials. Lancet Oncol 12: 65–82

    Google Scholar 

  • Bangalore S, Kumar S, Wetterslev J, Messerli FH (2011b): Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials. BMJ 342:d2234. doi: 10.1136

    Google Scholar 

  • Bangalore S, Kumar S, Messerli FH (2012): When Conventional Heart Failure Therapy is not Enough: Angiotensin Receptor Blocker, Direct Renin Inhibitor, or Aldosterone Antagonist? Congest Heart Fail. doi: 10.1111/ chf.12011

    Google Scholar 

  • Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J; Diabetics Exposed to Telmisartan and Enalapril Study Group (2004): Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 351: 1952–1961

    Google Scholar 

  • Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, Stoyanovsky V, Antikainen RL, Nikitin Y, Anderson C, Belhani A, Forette F, Rajkumar C, Thijs L, Banya W, Bulpitt CJ; HYVET Study Group (2008): Treatment of hypertension in patients 80 years of age or older. N Engl J Med 358: 1887–1898

    Google Scholar 

  • Beckett N, Peters R, Tuomilehto J, Swift C, Sever P, Potter J, McCormack T, Forette F, Gil-Extremera B, Dumitrascu D, Staessen JA, Thijs L, Fletcher A, Bulpitt C; HYVET Study Group (2012): Immediate and late benefits of treating very elderly people with hypertension: results from active treatment extension to Hypertension in the Very Elderly randomised controlled trial. BMJ 344: 1–10

    Google Scholar 

  • Bhaskaran K, Douglas I, Evans S, van Staa T, Smeeth L (2012): Angiotensin receptor blockers and risk of cancer: cohort study among people receiving antihypertensive drugs in UK General Practice Research Database. BMJ 344:e2697

    Google Scholar 

  • Blood Pressure Lowering Treatment Trialists’ Collaboration (2000): Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 356: 1955–1964

    Google Scholar 

  • Blood Pressure Lowering Treatment Trialists’ Collaboration (2007): Blood Pressure dependent and independent effects of agents that inhibit the renin-angiotensin system. J. Hypertension 25: 951–958 Blood Pressure Lowering Treatment Trialists’ Collaboration (2015): Effects of blood pressure lowering on cardiovascular risk according to baseline body-mass index: a meta-analysis of randomised trials. Lancet 385: 867–874

    Google Scholar 

  • Brown MJ (2008): Aliskiren. Circulation 118: 773–784

    Google Scholar 

  • Bundesärztekammer, Kassenärztliche Bundesvereinigung, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (2011): Nationale VersorgungsLeitlinie Nierenerkrankungen bei Diabetes im Erwachsenenalter 1. Auflage Version 1.3

    Google Scholar 

  • Burgess E, Muirhead N, Rene de Cotret P, Chiu A, Pichette V, Tobe S; SMART (Supra Maximal Atacand Renal Trial) Investigators (2009): Supramaximal dose of candesartan in proteinuric renal disease. J Am Soc Nephrol. 20: 893–900

    Google Scholar 

  • Carey RM (2013): Newly discovered components and actions of the renin-angiotensin system. Hypertension 62: 818–822

    Google Scholar 

  • Carter BL, Chrischilles EA, Rosenthal G, Gryzlak BM, Eisenstein EL, Vander Weg MW (2014): Efficacy and safety of nighttime dosing of antihypertensives: review of the literature and design of a pragmatic clinical trial. J Clin Hypertens (Greenwich) 16: 115–121

    Google Scholar 

  • Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, MacAllister RJ (2005): Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and metaanalysis. Lancet 366: 2026–2033

    Google Scholar 

  • Chang CH, Chang YC, Wu LC, Lin JW, Chuang LM, Lai MS (2014): Different angiotensin receptor blockers and incidence of diabetes: a nationwide population-based cohort study. Cardiovasc Diabetol 13: 91

    Google Scholar 

  • Cheng J, Zhang W, Zhang X, Han F, Li X, He X, Li Q, Chen J: Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. JAMA Intern Med 174: 773–785

    Google Scholar 

  • Cleland JG, Tendera M, Adamus J, Freemantle, Polonski L, Taylor J; PEP-CHF Investigators (2006): The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 27: 2338–2345

    Google Scholar 

  • Czernichow S, Zanchetti A, Turnbull F, Barzi F, Ninomiya T, Kengne AP, Lambers Heerspink HJ, Perkovic V, Huxley R, Arima H, Patel A, Chalmers J, Woodward M, MacMahon S, Neal B (2011): The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials. J Hypertens 29: 4–16

    Google Scholar 

  • Dickstein K, Kjekshus J, and the OPTIMAAL Steering Committee, for the OPTIMAAL Study Group (2002): Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 360: 752–760

    Google Scholar 

  • Elliott WJ, Meyer PM (2007): Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 369: 201–207

    Google Scholar 

  • Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A.: Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA 313: 603–615

    Google Scholar 

  • Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, Chalmers J, Rodgers A, Rahimi K (2016): Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 387: 957–967

    Google Scholar 

  • European Medicines Agency (2014): PRAC recommends against combined use of medicines affecting the renin-angiotensin (RAS) system. Press Release April 11, 2014; EMA/196502/2014

    Google Scholar 

  • FDA Drug Safety Communication (2013): FDA approves label changes to include intestinal problems (sprue-like enteropathy) linked to blood pressure medicine olmesartan medoxomil. 7-3-2013

    Google Scholar 

  • Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, Torp-Pedersen C, Ball S, Pogue J, Moye L, Braunwald E (2000): Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 355: 1575–1581

    Google Scholar 

  • Fralick M, Macdonald EM, Gomes T, Antoniou T, Hollands S, Mamdani MM, Juurlink DN; Canadian Drug Safety and Effectiveness Research Network (2014): Co-trimoxazole and sudden death in patients receiving inhibitors of renin-angiotensin system: population based study. BMJ 349: g6196

    Google Scholar 

  • Gandhi S, Fleet JL, Bailey DG, McArthur E, Wald R, Rehman F, Garg AX (2013): Calcium-channel blocker-clarithromycin drug interactions and acute kidney injury. JAMA 310: 2544–2553

    Google Scholar 

  • Granger CB, McMurray JJV, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K; CHARM Investigators and Committees (2003): Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362: 772–776

    Google Scholar 

  • Gheorghiade M, Bohm M, Greene SJ, Fonarow GC, Lewis EF, Zannad F, Solomon SD, Baschiera F, Botha J, Hua TA, Gimpelewicz CR, Jaumont X, Lesogor A, Maggioni AP; ASTRONAUT Investigators and Coordinators (2013): Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. Jama 309: 1125–1135

    Google Scholar 

  • Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, Menne J, Mimran A, Rabelink TJ, Ritz E, Ruilope LM, Rump LC, Viberti G; ROADMAP Trial Investigators (2011): Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 364: 907–917

    Google Scholar 

  • Hasenfuss G, Edelmann F, Wachter R (2013): Empfehlung zur Herzinsuffizienz Was gibt es Neues? Internist 54: 1141–1151

    Google Scholar 

  • Heerspink HL, de Zeeuw D (2010): Composite renal endpoints: was ACCOMPLISH accomplished? Lancet 375: 1140–1142

    Google Scholar 

  • Heerspink HJ, Ninomiya T, Perkovic V, Woodward M, Zoungas S, Cass A, Cooper M, Grobbee DE, Mancia G, Mogensen CE, Neal B, Chalmers J; ADVANCE Collaborative Group (2010): Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease. Eur Heart J 31: 2888–2896

    Google Scholar 

  • Heerspink HJ, Persson F, Brenner BM, Chaturvedi N, Brunel P, McMurray JJ, Desai AS, Solomon SD, Pfeffer MA, Parving HH, de Zeeuw D (2016): Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial. Lancet Diabetes Endocrinol 4: 309–317

    Google Scholar 

  • Hermida RC, Ayala DE, Mojón A, Fernández JR (2011a): Bedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD. J Am Soc Nephrol 22: 2313–2321

    Google Scholar 

  • Hermida RC, Ayala DE, Mojon A, Fernandez JR (2011b): Influence of time of day of blood pressure-lowering treatment on cardiovascular risk in hypertensive patients with type 2 diabetes. Diabetes Care 34: 1270–1276

    Google Scholar 

  • Hermida RC, Ayala DE, Mojon A, Fernandez JR (2016): Bedtime ingestion of hypertension medications reduces the risk of new-onset type 2 diabetes: a randomised controlled trial. Diabetologia 59: 255–265

    Google Scholar 

  • Hsu TW, Liu JS, Hung SC, Kuo KL, Chang YK, Chen YC, Hsu CC, Tarng DC (2014): Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia. JAMA Intern Med 174: 347–354

    Google Scholar 

  • Huang Y, Su L, Cai X, Mai W, Wang S, Hu Y, Wu Y, Tang H, Xu D (2014): Association of all-cause and cardiovascular mortality with prehypertension: a meta-analysis. Am Heart J 167: 160–168 el

    Google Scholar 

  • Imai E, Chan JC, Ito S, Yamasaki T, Kobayashi F, Haneda M, Makino H; ORIENT study investigators (2011): Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. Diabetologia 54: 2978–2986

    Google Scholar 

  • Jamerson K, Weber MA, Bakris GL, Dahlöf B et al. ACCOMPLISH Trial Investigators (2008): Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 359: 2417–2428

    Google Scholar 

  • Jamerson KA, Devereux R, Bakris GL, Dahlöf B, Pitt B, Velazquez EJ, Weir M, Kelly RY, Hua TA, Hester A, Weber MA (2011): Efficacy and duration of benazepril plus amlodipine or hydrochlorothiazide on 24-hour ambulatory systolic blood pressure control. Hypertension. 57: 174–179

    Google Scholar 

  • Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A; VALUE trial group (2004): Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363: 2022–2031

    Google Scholar 

  • Julius S, Nesbitt SD, Egan BM. for the Trial of Preventing Hypertension (TROPHY) Study Investigators (2006): Feasibility of treating prehypertension with an angiotensinreceptor blocker. N Engl J Med. 354: 1685–1697

    Google Scholar 

  • Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, Riegger GA, Malbecq W, Smith RD, Guptha S, Poole-Wilson PA; HEAAL Investigators (2009): Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 374: 1840–1848

    Google Scholar 

  • Kunz R, Friedrich C, Wolbers M, Mann JFE (2008): Meta-analysis: Effect of monotherapy and combination therapy with inhibitors of the renin-angiotensin system on proteinuria in renal disease. Ann Intern Med 148: 30–48

    Google Scholar 

  • Lakhdar R, Al-Mallah MH, Lanfear DE (2008): Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trials. J Card Fail 14: 181–188

    Google Scholar 

  • Levy BI (2004): Can angiotensin II Type 2 receptors have deleterious effects in cardiovascular disease? Circulation 109: 8–13

    Google Scholar 

  • Lewis EJ, Hunsicker LG, Bain RP, Rohde RD for the Collaborative Study Group (1993): The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329: 1456–1462

    Google Scholar 

  • Lonn EM, Bosch J, López-Jaramillo P, Zhu J, Liu L, Pais P, Diaz R, Xavier D, Sliwa K, Dans A, Avezum A, Piegas LS, Keltai K, Keltai M, Chazova I, Peters RJ, Held C, Yusoff K, Lewis BS, Jansky P, Parkhomenko A, Khunti K, Toff WD, Reid CM, Varigos J, Leiter LA, Molina DI, McKelvie R, Pogue J, Wilkinson J, Jung H, Dagenais G, Yusuf S; HOPE-3 Investigators (2016): Blood-pressure lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 374: 2009–2020

    Google Scholar 

  • Lüders S, Schrader J, Berger J, Unger T, Zidek W, Böhm M, Middeke M, Motz W, Lübcke C, Gansz A, Brokamp L, Schmieder RE, Trenkwalder P, Haller H, Dominiak P; PHARAO study group (2008): The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure - a prospective, randomized, controlled prevention trial of the German Hypertension League.

    Google Scholar 

  • J Hypertens 26: 1487–1496

    Google Scholar 

  • Lv Y, Zou Z, Chen GM, Jia HX, Zhong J, Fang WW (2010): Amlodipine and angiotensin-converting enzyme inhibitor combination versus amlodipine monotherapy in hypertension: a meta-analysis of randomized controlled trials. Blood Press Monit 15:195–204

    Google Scholar 

  • Lv J, Ehteshami P, Sarnak MJ, Tighiouart H, Jun M, Ninomiya T, Foote C, Rodgers A, Zhang H, Wang H, Strippoli GF, Perkovic V (2013): Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis. CMAJ 185: 949–957

    Google Scholar 

  • Makani H, Bangalore S, Desouza KA, Shah A, Messerli FH (2013): Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials. BMJ Jan 28; 346: f360. doi: 10.1136

    Google Scholar 

  • Malacco E, Santonastaso M, Vari NA, Gargiulo A, Spagnuolo V, Bertocchi F, Palatini P; Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril Study (2004): Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study. Clin Ther 26: 855–865

    Google Scholar 

  • Mann JFE, Schmieder RE, McQueen M, Dyal L et al. on behalf of the ONTARGET investigators (2008): Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 372: 547–553

    Google Scholar 

  • Mann JFE, Schmieder RE, Dyal L, McQueen MJ, Schumacher H, Pogue J, Wang X, Probstfield JL, Avezum A, Cardona-Munoz E, Dagenais GR, Diaz R, Fodor G, Maillon JM, Rydén L, Yu CM, Teo KK, Yusuf S; TRANSCEND (2009): Effect of telmisartan on renal outcomes: a randomized trial. Ann Intern Med 151: 1–10, W1-2

    Google Scholar 

  • Marott SC, Nielsen SF, Benn M, Nordestgaard BG (2014): Antihypertensive treatment and risk of atrial fibrillation: a nationwide study. Eur Heart J 35: 1205–1214

    Google Scholar 

  • Maschio G, Albert D, Ganin G, Locatelli F, Mann JFE et al. (1996): Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 334: 939–945

    Google Scholar 

  • Massie BM, Carson PE, McMurray JJ, Komajda M, et al. I-PRESERVE Investigators (2008): Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 359: 2456–2467

    Google Scholar 

  • McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Investigators and Committees (2014): Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371: 993–1004

    Google Scholar 

  • McMurray JJ, Krum H, Abraham WT, Dickstein K, Køber LV, Desai AS, Solomon SD, Greenlaw N, Ali MA, Chiang Y, Shao Q, Tarnesby G, Massie BM; ATMOSPHERE Committees Investigators (2016): Aliskiren, enalapril, or aliskiren and enalapril in heart failure. N Engl J Med 374: 1521–1532

    Google Scholar 

  • National Collaborating Centre for Chronic Conditions (2006): Hypertension: management of hypertension in adults in primary care: partial update. London: Royal College of Physicians. Internet:http://guidance.nice. org.uk/CG34/guidance.pdf/English

  • Nicholls SJ, Bakris GL, Kastelein JJ, Menon V, Williams B, Armbrecht J, Brunel P, Nicolaides M, Hsu A, Hu B, Fang H, Puri R, Uno K, Kataoka Y, Bash D, Nissen SE (2013): Effect of aliskiren on progression of coronary disease in patients with prehypertension: the AQUARIUS randomized clinical trial. JAMA 310: 1135–1144

    Google Scholar 

  • Oghlakian GO, Sipahi I, Fang JC (2011): Treatment of heart failure with preserved ejection fraction: have we been pursuing the wrong paradigm? Mayo Clin Proc 86: 531–539

    Google Scholar 

  • Padwal R, Lin M, Etminan M, Eurich DT (2014): Comparative effectiveness of olmesartan and other angiotensin receptor blockers in diabetes mellitus: retrospective cohort study. Hypertension 63: 977–983

    Google Scholar 

  • Palmer SC, Mavridis D, Navarese E, Craig JC, Tonelli M, Salanti G, Wiebe N, Ruospo M, Wheeler DC, Strippoli GF (2015) Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet 385: 2047–2056

    Google Scholar 

  • Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA; ALTITUDE Investigators (2012): Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 367: 2204–2213

    Google Scholar 

  • Pierre-Louis B, Rodriques S, Gorospe V, Guddati AK, Aronow WS, Ahn C, Wright M (2016): Clinical factors associated with early readmission among acutely decompensated heart failure patients. Arch Med Sci 12: 538–545

    Google Scholar 

  • Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B (2000): Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 355: 15821587

    Google Scholar 

  • Pitt B (2004): ACE inhibitors for patients with vascular disease without left ventricular dysfunction - may they rest in PEACE? N Engl J Med 351: 2115–2117

    Google Scholar 

  • Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P; Authors/Task Force Members; Document Reviewers (2016): 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J May 20, DOI: http://dx.doi.org/10.1093/eurheartj/ehw128

    Google Scholar 

  • Rector TS, Carson PE, Anand IS, McMurray JJ, Zile MR, Mc-Kelvie RS, Komajda M, Kuskowski M, Massie BM; I-PRESERVE Trial Investigators (2012): Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial. Circ Heart Fail 5: 217–225

    Google Scholar 

  • Roush GC, Fapohunda J, Kostis JB (2014): Evening dosing of antihypertensive therapy to reduce cardiovascular events: a third type of evidence based on a systematic review and meta-analysis of randomized trials. J Clin Hypertens 16: 561–568

    Google Scholar 

  • Rubio-Tapia A, Herman ML, Ludvigsson JF, Kelly DG, Mangan TF, Wu TT, Murray JA (2012): Severe spruelike enteropathy associated with olmesartan. Mayo Clin Proc 87: 732–738

    Google Scholar 

  • Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, Rubis N, Gherardi G, Arnoldi F, Ganeva M, Ene-Iordache B, Gaspari F, Perna A, Bossi A, Trevisan R, Dodesini AR, Remuzzi G; Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators (2004): Preventing microalbuminuria in type 2 diabetes. N Engl J Med 351: 1941–1951

    Google Scholar 

  • Sakata Y, Shiba N, Takahashi J, Miyata S, Nochioka K, Miura M, Takada T, Saga C, Shinozaki T, Sugi M, Nakagawa M, Sekiguchi N, Komaru T, Kato A, Fukuchi M, Nozaki E, Hiramoto T, Inoue K, Goto T, Ohe M, Tamaki K, Ibayashi S, Ishide N, Maruyama Y, Tsuji I, Shimokawa H; SUPPORT Trial Investigators (2015): Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: the supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial. Eur Heart J 36:915–923

    Google Scholar 

  • Sandset EC, Bath PM, Boysen G, Jatuzis D, Kõrv J, Luders S, Murray GD, Richter PS, Roine RO, Terént A, Thijs V, Berge E; SCAST Study Group (2011): The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. Lancet 377: 741–750

    Google Scholar 

  • Sato A, Fukuda S (2015): A prospective study of frequency and characteristics of cough during ACE inhibitor treatment. Clin Exp Hypertens 37: 563–568

    Google Scholar 

  • Schmieder RE, Klingbeil AU, Fleischmann EH, Veelken R, Delles C (2005): Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study. J Am Soc Nephrol. 16: 3038–3045

    Google Scholar 

  • Schmieder RE, Hilgers KF, Schlaich MP, Schmidt MW (2007): Renin angiotensin system and cardiovascular risk. Lancet 369: 1208–1219

    Google Scholar 

  • Schmidt SA, Schmidt M, Mehnert F, Lemeshow S, Sorensen HT. (2015): Use of antihypertensive drugs and risk of skin cancer. J Eur Acad Dermatol Venereol 29: 1545–1554 Schneider MP, Hua TA, Bohm M, Wachtell K, Kjeldsen SE, Schmieder RE (2010): Prevention of atrial fibrillation by Renin-Angiotensin system inhibition a meta-analysis. J Am Coll Cardiol. 55: 2299–2307

    Google Scholar 

  • Schrader J, Luders S, Kulschewski A, Berger J, Zidek W, Treib J, Einhaupl K, Diener HC, Dominiak P; Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group (2003): The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke 234: 16991703

    Google Scholar 

  • Schrader J, Lüders S, Kulschewski A, Hammersen F, Plate K, Berger J, Zidek W, Dominiak P, Diener HC; MOSES Study Group (2005): Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention. Principal results of a prospective randomized controlled study (MOSES). Stroke 36: 1218–1226

    Google Scholar 

  • Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC (2010): Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol 11: 627–636

    Google Scholar 

  • Staessen JA, Li Y, Thijs L, Wang JG (2005): Blood pressure reduction and cardiovascular prevention: an update including the 2003–2004 secondary prevention trials. Hypertens Res 28: 385–407

    Google Scholar 

  • Staessen JA, Richart T, Wang Z, Thijs L (2010): Implications of recently published trials of blood pressure-lowering drugs in hypertensive or high-risk patients. Hypertension 55:819–831

    Google Scholar 

  • Svensson P, de Faire U, Sleight P, Yusuf S, Jan Östergren J (2001): Comparative effects of ramipril on ambulatory and office blood pressures. A HOPE substudy. Hypertension 38: e28-e32

    Google Scholar 

  • The ACTIVE I Investigators (2011): Irbesartan in patients with atrial fibrillation. N Engl J Med 364: 928–938

    Google Scholar 

  • The DREAM Trial Investigators (2006): Effect of ramipril on the incidence of diabetes. N Engl J Med 355: 1551–1562 The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators (2003): Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362: 782–788

    Google Scholar 

  • The GISEN Group (1997): Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349: 1857–1863

    Google Scholar 

  • The GISSI-AF Investigators (2009): Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 360: 1606–1617

    Google Scholar 

  • The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators (2000): Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342: 145–153

    Google Scholar 

  • The ONTARGET Investigators (2008): Telmisartan, ramipril or both in patients at high risk for vascular events. N Engl J Med 358: 1547–1559

    Google Scholar 

  • The Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators (2008): Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 372: 1174–1183

    Google Scholar 

  • Thompson AM, Hu T, Eshelbrenner CL, Reynolds K, He J, Bazzano LA. (2011): Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysis. JAMA 305: 913–922

    Google Scholar 

  • Verma S, Strauss M (2004): Angiotensin receptor blockers and myocardial infarction. These drugs may increase myocardial infarction - and patients may need to be told. BMJ 329: 1248–1249

    Google Scholar 

  • Wachtell K, Hornestam B, Lehto M, Slotwiner DJ, Gerdts E, Olsen MH, Aurup P Dahlöf B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Rokkedal J, Devereux RB (2005a): Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 45: 705–711

    Google Scholar 

  • Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlöf B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Devereux RB (2005b): Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.

    Google Scholar 

  • J Am Coll Cardiol. 45: 712–719

    Google Scholar 

  • Weber MA, Jamerson K, Bakris GL, Weir MR, Zappe D, Zhang Y, Dahlof B, Velazquez EJ, Pitt B (2013): Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. Lancet 381: 537–545

    Google Scholar 

  • Williamson JD, Supiano MA, Applegate WB, Berlowitz DR, Campbell RC, Chertow GM, Fine LJ, Haley WE, Hawfield AT, Ix JH, Kitzman DW, Kostis JB, Krousel-Wood MA, Launer LJ, Oparil S, Rodriguez CJ, Roumie CL, Shorr RI, Sink KM, Wadley VG, Whelton PK, Whittle J, Woolard NF, Wright JT Jr, Pajewski NM; SPRINT Research Group (2016): Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged>/ = 75 Years: A randomized clinical trial. JAMA 2016; published online May 19. doi:10.1001/jama.2016.7050

    Google Scholar 

  • Xie X, Atkins E, Lv J, Bennett A, Neal B, Ninomiya T, Woodward M, MacMahon S, Turnbull F, Hillis GS, Chalmers J, Mant J, Salam A, Rahimi K, Perkovic V, Rodgers A (2016a): Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet 387: 435–443

    Google Scholar 

  • Xie X, Atkins E, Lv J, Rodgers A. (2016b): Intensive blood pressure lowering. Author’s reply. Lancet 387: 2291

    Google Scholar 

  • Yang R, Luo Z, Liu Y, Sun M, Zheng L, Chen Y, Li Y, Wang H, Chen L, Wu M, Zhao H (2016): Drug Interactions with Angiotensin Receptor Blockers: Role of Human Cytochromes P450. Curr Drug Metab May 24, ahead of print.

    Google Scholar 

  • Yusuf S (2002): From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. Am J Cardiol 89 (2 A): 18 A-25 A Yusuf S (2002): From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. Am J Cardiol 89: 18 A-25 A

    Google Scholar 

  • Yusuf S, Diener HC, Sacco RL, Cotton D, Ôunpuu S for the PRoFESS Study Group (2008): Telmisartan to prevent recurrent stroke and cardiovascular Events. N Engl J Med 359: 1225–1237

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Friedrich-Plettke-Weg 12, 27570, Bremerhaven

    Prof. Dr. med. Manfred Anlauf

  2. Thiemannstraße 18, 45219, Essen

    Prof. Dr. med. Franz Weber

Authors
  1. Prof. Dr. med. Manfred Anlauf
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. Franz Weber
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut, Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Ulrich Schwabe

  2. Bachstraße 29, 50858, Köln

    Dieter Paffrath

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Anlauf, M., Weber, F. (2016). Hemmstoffe des Renin-Angiotensin-Systems. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2016. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-50351-5_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-50351-5_8

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-50350-8

  • Online ISBN: 978-3-662-50351-5

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation